​

Inozyme Pharma (INZY) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

INZY Stock Forecast

Inozyme Pharma (INZY) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $14.67, with a high of $16.00 and a low of $14.00. This represents a 1428.12% increase from the last price of $0.96.

- $4 $8 $12 $16 $20 High: $16 Avg: $14.67 Low: $14 Last Closed Price: $0.96

INZY Stock Rating

Inozyme Pharma stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 9 Strong Sell Sell Hold Buy Strong Buy

INZY Price Target Upside V Benchmarks

TypeNameUpside
StockInozyme Pharma1428.13%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$15.00
Last Closing Price$0.96$0.96$0.96
Upside/Downside--1462.50%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2545---9
Mar, 2545---9
Feb, 2545---9
Jan, 2546---10
Dec, 2446---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 11, 2024Dae Gon HaStifel Nicolaus$16.00$5.21207.10%1566.67%
May 30, 2024Tiago FauthWells Fargo$14.00$4.51210.42%1358.33%
Apr 09, 2024Edward WhiteH.C. Wainwright$14.00$5.87138.50%1358.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 12, 2025Wells FargoOverweightOverweighthold
Jan 10, 2025H.C. WainwrightBuyBuyhold
May 30, 2024Wells FargoOverweightinitialise
Apr 09, 2024H.C. WainwrightBuyBuyhold
Apr 09, 2024Bank of America SecuritiesBuyBuyhold
Mar 23, 2023JefferiesBuyupgrade
Jul 19, 2022Piper SandlerOverweightOverweighthold
Nov 30, 2021NeedhamBuyinitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.37$-1.62----
Avg Forecast$-1.34$-1.60$-1.61$-1.61$-1.27$-0.86
High Forecast$-1.31$-1.52$-1.37$-0.89$-0.79$-0.86
Low Forecast$-1.40$-1.68$-1.96$-2.17$-1.91$-0.86
Surprise %2.24%1.25%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$8.01M$53.59M$151.28M
High Forecast---$8.01M$53.59M$151.28M
Low Forecast---$8.01M$53.59M$151.28M
Surprise %------

Net Income Forecast

$-115M $-100M $-85M $-70M $-55M $-40M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-71.17M$-102.02M----
Avg Forecast$-71.17M$-82.80M$-86.34M$-79.30M$-69.93M$-44.81M
High Forecast$-68.13M$-78.63M$-71.10M$-45.96M$-40.90M$-44.81M
Low Forecast$-72.81M$-86.96M$-101.57M$-112.63M$-98.96M$-44.81M
Surprise %-23.22%----

INZY Forecast FAQ

Is Inozyme Pharma stock a buy?

Inozyme Pharma stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Inozyme Pharma is a favorable investment for most analysts.

What is Inozyme Pharma's price target?

Inozyme Pharma's price target, set by 9 Wall Street analysts, averages $14.67 over the next 12 months. The price target range spans from $14 at the low end to $16 at the high end, suggesting a potential 1428.12% change from the previous closing price of $0.96.

How does Inozyme Pharma stock forecast compare to its benchmarks?

Inozyme Pharma's stock forecast shows a 1428.12% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Inozyme Pharma over the past three months?

  • April 2025: 44.44% Strong Buy, 55.56% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 44.44% Strong Buy, 55.56% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 44.44% Strong Buy, 55.56% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Inozyme Pharma’s EPS forecast?

Inozyme Pharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.61, marking a -0.62% decrease from the reported $-1.62 in 2024. Estimates for the following years are $-1.61 in 2026, $-1.27 in 2027, and $-0.86 in 2028.

What is Inozyme Pharma’s revenue forecast?

Inozyme Pharma's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $8.01M, followed by $53.59M for 2027, and $151.28M for 2028.

What is Inozyme Pharma’s net income forecast?

Inozyme Pharma's net income forecast for the fiscal year ending in December 2025 stands at $-86.338M, representing a -15.37% decrease from the reported $-102M in 2024. Projections indicate $-79.298M in 2026, $-69.93M in 2027, and $-44.807M in 2028.